Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  UCB    UNC   BE0003739530

UCB (UNC)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on UCB
01/19 UCB S.A. REPORTS FINDINGS IN PARKINS : A randomized,...
01/12 Pfizer's Barrett named CEO of Novartis Oncology
01/11 AMGEN : European Medicines Agency Accepts Filing for EVENITY
01/09 UCB : European Medicines Agency Accepts Filing for EVENITYTM
01/04 DATA ON PSORIATIC ARTHRITIS DISCUSSE : ...
2017 European stocks sink on Flynn guilty plea after choppy session
2017 European stocks sink on Flynn guilty plea after choppy session
2017 UCB : Research Conducted at UCB S.A. Has Provided New Information about Clinical..
2017 UCB : New study data shows prior osteoporotic fractures put women at increased r..
2017 DERMIRA : and UCB Agree to End Collaboration Agreement for CIMZIA
2017 UCB : Dermira and UCB Agree to End Collaboration Agreement for CIMZIA …
2017 UCB FIRST NINE MONTHS INTERIM REPORT :  Strong 9 …
2017 UCB : By the time you finish reading this headline another person …
2017UCB SA : quaterly earnings release
2017 UCB : Transparency notification The Capital Group Companies
2017 UCB : Transparency notification The Capital Group Companies
2017 UCB : Studies from UCB S.A. Reveal New Findings on Extracellular Space (Quantita..
2017 NEW INDICATION FOR BRIVIACT® (BRIVAR : UCB’s newest antiepileptic drug &he..
2017 UCB : New CIMZIA® (certolizumab pegol) Findings Presented at European Academy of..
2017 UCB : EVENITYTM (romosozumab) ARCH Study Results Published in the New England &h..
2017 UCB : highlights latest EVENITY™ (romosozumab) research at the American So..
2017 UCB : S.A. - Transparency notification Wellington
2017 UCB : Findings on Epilepsy Detailed by Investigators at UCB S.A. (Lacosamide and..
2017 UCB : Transparency notification Wellington
2017 UCB : Researchers from UCB S.A. Report on Findings in Lupus (Repeated administra..
2017 UCB : Reports Summarize Parkinson's Disease Study Results from UCB S.A. (U18666A..
2017 UCB : S.A. - Transparency notification The Capital Group Companies
2017 UCB : Transparency Notification the Capital Group Companies
2017 UCB : Amgen And UCB Provide Update On Regulatory Status Of EVENITY romosozumab I..
2017 UCB : with a strong first half year 2017 – giving rise …
2017 UCB : and Dermira Announce U.S. and EU Regulatory Submissions …
2017 UCB : anti-epileptic drug VIMPAT® (lacosamide) receives EU CHMP …
2017 UCB : Bimekizumab Demonstrates Skin Clearance in Phase 2b Psoriasis Study with &..
2017 UCB : and Amgen Provide Update on Regulatory Status of EVENITY …
2017 UCB : Study Findings on Clinical Pharmacology Are Outlined in Reports from UCB S..
2017 UCB : Outcome Capital Announces UCB Pharma Has Acquired Beryllium Discovery
2017 UCB : New study illustrates large treatment gap in post-fracture care …
2017 UCB : announces four-year imaging results demonstrating low disease progression ..
2017 UCB : Results from CRIB study on CIMZIA® (certolizumab pegol) demonstrate minima..
2017 UCB : New UCB data demonstrates scientific innovation for immunology patients wi..
2017 UCB : Research!America - Briefing
2017 UCB : Research!America - Briefing
2017 UCB : Transparency notification BlackRock, Inc.
2017 UCB : Transparency notification
2017 UCB : Transparency notifications BlackRock, Inc.
2017 UCB : New Findings on Epilepsy from UCB S.A. Summarized (Patient emotions and pe..
2017 UCB : Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study ..
2017 UCB : Transparency notification
2017 UCB : and Amgen announce top-line phase 3 data from …
2017 UCB : Transparency notification
2017 Attention Deficit Hyperactivity Disorder ADHD Drug Sales Market 2017 - Shire,..
2017 UCB : ex-dividend day for annual dividend
2017 UCB : General Meeting of Shareholders
2017 UCB : receives positive CHMP opinion for CIMZIA® (certolizumab pegol) dose &hell..
2017 UCB FIRST THREE MONTHS INTERIM REPOR :  UCB with …
2017 UCB : Findings from UCB S.A. Provides New Data on Epilepsy (Health care cost ass..
2017UCB SA : quaterly earnings release
2017 UCB : U.S. Patent and Trademark Office confirms validity of patent …
2017 UCB : Acquisition of own shares
2017 UCB : Acquisition of own shares
2017 UCB : and Q-State Biosciences Form Research Collaboration …
2017 AMGEN : Ucb and amgen report new data at endo 2017 examining the option of a sec..
2017 UCB : AND AMGEN REPORT NEW DATA AT ENDO 2017 EXAMINING …
2017 UCB : General Meeting on 27 April 27 2017
2017 UCB : Convening notice to attend the general meeting of shareholders
2017 UCB : U.S. Patent and Trademark Office confirms validity of patent …
2017 UCB : Brussels - Transparency notifications
2017 UCB : Transparency notifications
2017 UCB : Acquisition of own shares
2017 UCB : Researchers from UCB S.A. Report New Studies and Findings in the Area of E..
2017 UCB : Transparency notification
2017 SCHEDULES OF CONTROLLED SUBSTANCES : Placement of Brivaracetam Into Schedule V
2017 UCB : Transparency notification
2017 UCB : Transparency notification
2017 UCB : New CIMZIA (certolizumab pegol) data in moderate-to-severe plaque psoriasi..
1  2  3  4  5  6Next
Financials (€)
Sales 2017 4 394 M
EBIT 2017 1 019 M
Net income 2017 667 M
Debt 2017 516 M
Yield 2017 1,77%
P/E ratio 2017 19,20
P/E ratio 2018 16,96
EV / Sales 2017 3,22x
EV / Sales 2018 2,99x
Capitalization 13 615 M
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 18
Average target price 67,1 €
Spread / Average Target -4,1%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB2.54%16 637
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132